OrthoPediatrics Corp

OrthoPediatrics Corp(KIDS)股票分析

$24.500

-0.208 (-0.85%)收盤時

Loading chart…
最高
24.700
開盤
24.430
成交量加權均價
24.32
成交量
174.63K
市值
686.03M
最低
23.750
成交金額
4.25M
企業價值/稅息折舊攤銷前利潤(TTM)
142.28

OrthoPediatrics Corp. is an orthopedic company, which is focused on advancing the field of pediatric orthopedics. The Company is engaged in designing, developing, and marketing anatomically appropriate implants and devices for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers. The Company sells its specialized products, including PediLoc, PediPlates, Cannulated Screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System and Mitchell Ponset specialized bracing products to various hospitals and medical facilities throughout the United States and various international markets. It markets 80 surgical and specialized bracing systems.

AI 分析 of OrthoPediatrics Corp (KIDS)

買進

OrthoPediatrics Corp (KIDS) is a good buy right now due to its current price of $24.50, which is well below the analyst price target of $29 set by BTIG, indicating a potential upside of 18.37%. Additionally, the company has shown a strong revenue growth of 15.4% year-over-year in Q2, with a gross margin of 74%, which reflects operational efficiency. However, the main risk is the negative earnings per share (EPS) of -0.30 reported in Q2, which highlights ongoing profitability challenges.

分析師評級(4)

-6.12% 下跌空間
買進
4 買進
0 持有
0 賣出
目前: 24.50
最低
20.00
平均
23.00
最高
26.00

BTIG

2026-08-20

目標價

$29

買進

Truist

2026-08-05

目標價

$22

持有

Truist

2026-05-01

目標價

$17

持有

Canaccord

2026-04-24

目標價

$25

買進

Truist

2026-03-02

目標價

$20

持有

估值指標

OrthoPediatrics Corp(KIDS)目前預期本益比為 0.00,5 年平均預期本益比為 -39.38。

預期本益比

嚴重高估
5 年均值 P/E
-39.38
目前P/E
0.00
高估
-20.17
低估
-58.58

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
91.99
目前EV/EBITDA
142.28
高估
180.96
低估
3.02

預期股價營收比

合理
5 年均值 P/S
4.33
目前P/S
2.16
高估
6.91
低估
1.76

Alphio AI 對 KIDS 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%KIDS

$28.44

情境價格

基

基準

基準 · 50%KIDS

$28.41

情境價格

悲

悲觀

悲觀 · 25%KIDS

$23.50

情境價格

持有 KIDS 的大戶

B

Braidwell LP

+ 持有KIDS

+24.47%

3個月報酬率

S

Soleus Capital Management, L.P.

+ 持有KIDS

-6.31%

3個月報酬率

事件時間軸

2026-04-30 (ET)

17:30:00

OrthoPediatrics Launches Traxio Complete Weight System

16:40:00

OrthoPediatrics Q1 Revenue $59.36M, Exceeds Expectations

2026-02-03 (ET)

07:10:00

OrthoPediatrics Partner iotaMotion Receives FDA Clearance for Expanded Pediatric Use

2026-01-12 (ET)

07:20:00

Generated Company Reports $236.1M Net Revenue for 2025

07:20:00

OrthoPediatrics Projects 2026 Revenue of $262M to $266M

資訊

KIDS 常見問題 —— 由 Alphio AI 解答

OrthoPediatrics Corp. is an orthopedic company, which is focused on advancing the field of pediatric orthopedics. The Company is engaged in designing, developing, and marketing anatomically appropriate implants and devices for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers. The Company sells its specialized products, including PediLoc, PediPlates, Cannulated Screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System and Mitchell Ponset specialized bracing products to various hospitals and medical facilities throughout the United States and various international markets. It markets 80 surgical and specialized bracing systems. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

OrthoPediatrics Corp (KIDS) is a good buy right now due to its current price of $24.50, which is well below the analyst price target of $29 set by BTIG, indicating a potential upside of 18.37%. Additionally, the company has shown a strong revenue growth of 15.4% year-over-year in Q2, with a gross margin of 74%, which reflects operational efficiency. However, the main risk is the negative earnings per share (EPS) of -0.30 reported in Q2, which highlights ongoing profitability challenges.

4 analysts cover KIDS: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 23.00.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易